Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.70
Bid: 4.70
Ask: 5.99
Change: -0.43 (-8.38%)
Spread: 1.29 (27.447%)
Open: 4.70
High: 4.70
Low: 4.70
Prev. Close: 5.13
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Data Presented at ESWI Influenza Conference

8 Dec 2021 07:00

RNS Number : 8998U
Synairgen plc
08 December 2021
 

 

Press Release

 

Synairgen plc 

('Synairgen' or the 'Company') 

Synairgen Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference

· In vitro data demonstrate antiviral activity of SNG001 against multiple variants of SARS-CoV-2

· Clinical biomarker data show inhaled SNG001 stimulates lung antiviral responses

 

Southampton, UK - 8 December 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of severe viral lung infections, has presented in vitro and clinical data demonstrating antiviral activity for SNG001 in a poster and an oral presentation respectively at the 8th European Scientific Working Group in Influenza (ESWI) Influenza Conference, which was held virtually 4-7 December, 2021.

In the poster session, Synairgen presented in vitro data demonstrating that SNG001, our formulation of the naturally-occurring antiviral protein interferon beta, potently reduced virus to undetectable levels in cells infected with SARS-CoV-2 including the Alpha, Beta and Gamma variants of concern (VOC), at concentrations that are readily achievable following inhaled delivery of interferon beta.

"This study demonstrated potent antiviral activity of SNG001 against SARS-CoV-2 including Alpha, Beta and Gamma variants, which is important given the continuing emergence and global spread of variants of concern," Phillip Monk, Ph.D., Synairgen Chief Scientific Officer, commented.

Synairgen is investigating the in vitro activity of SNG001 against the Delta and Omicron variants of SARS-CoV-2 and will make data available as soon as possible.

In a separate oral session on 6 December, Dr Monk presented data showing that inhaled SNG001 significantly increased interferon beta-dependent antiviral biomarkers in the lungs of asthma and chronic obstructive pulmonary disease (COPD) patients enrolled in Phase 2 trials.

"SNG001 is an investigational drug currently in Phase 3 trials, with the first data read out early in 2022, and contains the essential antiviral protein interferon beta, a protein that 'switches on' antiviral defences. Interferon beta production by lung cells is suppressed by the SARS-CoV-2 virus. We presented data showing that SNG001 activates the lungs' antiviral defences for 24 hours after a dose has been delivered, supporting our once-a-day dosing schedule," Dr Monk added.

 

 

 

Details of the two ESWI presentations are as follows:

Poster Presentation:

Title: Interferon beta has potent antiviral activity against SARS-CoV-2 including variants of concern

Abstract: 269

Vero E6 cells, a cell line that is widely used in virology studies, were pre-treated with SNG001 16 hours before, and re-treated with SNG001 after, infection with 'Wuhan-like' SARS-CoV-2, Alpha, Beta or Gamma variants. The presence of viral protein-positive cells was determined 20 hours post-infection by immunostaining.

The poster included the following data:

· SNG001 potently reduced virus to undetectable levels following infection of cells with 'Wuhan-like' SARS-CoV-2, Alpha, Beta or Gamma variants.

· SNG001 achieved 99% inhibition (IC99) at concentrations of 5.4, 17.7, 11.0 and 7.9 IU/mL respectively.

The poster presentation is available on the Synairgen website.

Oral Presentation:

Title: Local delivery of interferon beta (SNG001) by inhalation upregulates lung antiviral biomarkers

Abstract: 270

Sputum samples were collected from patients in two Phase 2 studies of SNG001: SG005 (NCT01126177) in patients with asthma, and SG015 (NCT03570359) in patients with COPD. Gene expression of IFN-β-dependent antiviral biomarkers, MX1 and OAS1, in cells in the sputum samples were measured by RT-qPCR.

The presentation included the following data:

· Inhaled SNG001 significantly increased levels of interferon beta-dependent antiviral biomarkers in the lungs of both patient populations compared with pre-treatment levels.

· Biomarker responses were similar in younger asthma patients and older COPD patients at the same dose.

· SNG001 was well tolerated.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR').

 

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Chief Financial Officer

Brooke Clarke, Head of Communications

Brooke.Clarke@synairgen.com Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

 

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

 

Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

MKC STRATEGIES, LLC (US Media Relations) 

Mary Conway

MConway@MKCStrategies.com

Tel: +1 516-606-6545

 

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA) and the Phase 3 SPRINTER trial was deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). Synairgen's Phase 3 clinical programme is currently evaluating nebulised SNG001 in patients across 17 countries. In a Phase 2 trial in hospitalised COVID-19 patients, SNG001 demonstrated a greater than two-fold chance of recovery to 'no limitation of activities' versus placebo.1

Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.

1https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDBBDDSDGDGBR
Date   Source Headline
15th Nov 20237:00 amRNSGrant of Options
11th Oct 20237:00 amRNSAppointment of New Chief Financial Officer
3rd Oct 20237:00 amRNSAppointment of Chief Medical Officer
21st Sep 20237:00 amRNSInterim Results
29th Jun 20236:02 pmRNSResult of AGM
29th Jun 202310:00 amRNSAnnual General Meeting Presentation
22nd Jun 20237:00 amRNSGrant of Options
23rd May 20237:00 amRNSPosting of Annual Report and Notice of AGM
27th Apr 20237:00 amRNS2022 Full Year Results
17th Apr 20237:00 amRNSNotice of Full Year results
13th Mar 20234:40 pmRNSSecond Price Monitoring Extn
13th Mar 20234:35 pmRNSPrice Monitoring Extension
3rd Feb 20234:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Jan 20234:40 pmRNSSecond Price Monitoring Extn
13th Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Dec 202211:30 amRNSSPRINTER Trial Results Published
14th Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSBoard Changes
7th Nov 20224:40 pmRNSSecond Price Monitoring Extn
7th Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20224:40 pmRNSSecond Price Monitoring Extn
3rd Nov 20224:35 pmRNSPrice Monitoring Extension
20th Oct 20224:35 pmRNSPrice Monitoring Extension
6th Oct 20221:35 pmRNSHolding(s) in Company
4th Oct 20227:02 amRNSData from the US NIH-led ACTIV-2 Phase 2 trial
29th Sep 20227:01 amRNSBoard Changes
29th Sep 20227:00 amRNSInterim Results
20th Sep 20227:00 amRNSSPRINTER Long COVID data presented at IDWeek
15th Sep 20227:00 amRNSNotice of Interim Results
8th Sep 20224:40 pmRNSSecond Price Monitoring Extn
8th Sep 20224:35 pmRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSPositive Findings from SG015 Tri-al Analysis
5th Sep 20227:00 amRNSCompany Announce Collaboration on UNIVERSAL Trial
6th Jul 20227:00 amRNSGrant of Options
30th Jun 20221:45 pmRNSResult of AGM
23rd Jun 20224:40 pmRNSSecond Price Monitoring Extn
23rd Jun 20224:35 pmRNSPrice Monitoring Extension
15th Jun 20222:30 pmRNSHolding(s) in Company
9th Jun 20223:00 pmRNSExercise of Options and Total Voting Rights
6th Jun 20224:25 pmRNSPosting of Annual Report & Notice of AGM
25th May 20227:00 amRNSFull Year Results
18th May 20224:36 pmRNSPrice Monitoring Extension
16th May 20227:00 amRNSSynairgen presents at ATS 2022
25th Apr 20227:00 amRNSPresentation at ECCMID
19th Apr 20224:40 pmRNSSecond Price Monitoring Extn
19th Apr 20224:35 pmRNSPrice Monitoring Extension
6th Apr 20222:10 pmRNSHolding(s) in Company
5th Apr 20227:00 amRNSSynairgen to present at ATS 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.